Interferon gamma biosimilar - Nanogen Biopharmaceutical

Drug Profile

Interferon gamma biosimilar - Nanogen Biopharmaceutical

Alternative Names: Recombinant human interferon gamma

Latest Information Update: 12 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanogen Biopharmaceutical Co
  • Class Antineoplastics; Interferons; Lymphokines
  • Mechanism of Action Immunostimulants; Interferon gamma stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chronic granulomatous disease; Osteopetrosis

Most Recent Events

  • 12 Mar 2014 Preclinical trials in Chronic granulomatous disease in Vietnam (SC)
  • 12 Mar 2014 Preclinical trials in Osteopetrosis in Vietnam (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top